HUBBARD, Ohio, May 11 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink Sheets: NNLX) is pleased to announce the creation of its Science Advisory Board to help evaluate and target research and development efforts for products. The new advisory board provides the company with a vastly expanded scope of expertise in both medicine and biomedical research.
Dr. Robert Ollar, NanoLogix cofounder and author of numerous NanoLogix patents, has resigned from the NanoLogix Board of Directors to assume the position of Chairman of the Science Advisory Board.
NanoLogix Science Advisory Board Members
Dr. Robert A. Ollar, M. Sc., Ph.D.
Chairman of the Science Advisory Board. Dr. Ollar is the director of the Core Molecular Biology Program of the Department of Surgery at St. Vincent's Hospital in Manhattan. He is also an Assistant Professor at
He brings to the Board decades of experience in the fields of medical microbiology, mycobacteriology, medical mycology, and molecular biology. He serves as advisor to the WHO Global Stop TB Partnership, CDC TB Training and Educational Network, and the Mahatma Gandhi Institute for Medical Sciences in India in the fields of TB and AIDS-related mycobacterial Diseases.
Dr. Ollar's current focus is on the development of molecular technologies for rapid detection of pancreatic and colorectal cancers.
Sergey V. Gazenko, Ph.D., NanoLogix Vice-President of Research and Development. Dr. Gazenko holds his doctoral degree from The Institute of Applied Biochemistry in Moscow. Dr. Gazenko has worked for more than 28 years in the area of microbiological diagnostics and is the author of numerous scientific publications and patents. He is the author of both granted and patents pending for BNP(TM) and BNC(TM) rapid test kits. His current focus is on enhancements to both BNP and BNC technologies.
Dr. Brian Caplin, Ph.D.
Dr. Caplin holds a doctorate in the fields of biochemistry and molecular biology. He is an internationally respected expert in the new field of Real Time Polymerase Chain Reaction and is president of his own firm, Fluoresentric, Inc. He brings to the advisory board an extensive insight into the links of traditional growth-based technologies to the expanding world of real time diagnostics and microarray-based systems for the identification of large panels of microbial pathogens, important in areas such as medical veterinary microbiology and biodefense.
Dr. T. Dorai, M.Sc., Ph.D.
Associate Professor and Director of Research, Department of Urology, Saint Vincent's Hospital and
Dr. Sushil Duddempudi, MD
Assistant Professor of Medicine,
Dr. Deepak Kumar Mendiratta, MD, Ph.D.
Dr. Mendiratta is chairman of the Department of Microbiology at the Mahatma Gandhi Institute of Medical Sciences. He holds both scientific and medical graduate and post-graduate credentials.
Dr. Mrs. P. Narang, MD
Dr. Narang is an internationally respected physician in the fields of microbiology, medical education, and public health. Formerly dean of the Mahatma Gandhi Institute of Medical Science, and chairman of its Department of Microbiology, she has lectured worldwide on Public Health topics related to infections disease pathogens, especially in the realm of Global TB. Dr. Narang pioneered the field of AIDS-related non-tuberculous mycobacterial research in India, increasing awareness throughout India of the importance of prompt identification and treatment of these pathogens in the Indian AIDS patient population.
Dr. Ravinder Narang, MD
An internationally respected surgeon and educator, Dr. Narang has written extensively on infectious disease and oncology and participated in numerous programs involving both national and international (WHO) public health agencies. He brings to the Science Advisory Board a surgeon's unique perspective on operative and post-operative complications related to infectious agents.
Cliff Watts, MD
Dr. Watts has been an Emergency Room physician for almost thirty-five years. During his tenure at Boulder Community Hospital, Dr. Watts has often been on the front line of treating patients with life threatening diseases, and has a practical understanding of the needs in rapid response medicine. His contribution to the board is based upon extensive practical experience in urgent care, public health, and time-sensitive response to treatment.
Chris Novak, NanoLogix Director of Intellectual Property. Mr. Novak is a registered patent attorney and is licensed to practice law in several states. Mr. Novak earned a Juris Doctor (J.D.) degree from
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in infectious and non-infectious human diseases, such as tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis, anthrax, and plague. In addition to medical, Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation.
More information on NanoLogix is available at: www.nanologix.com
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contact: NanoLogix, Inc. Investor Relations Carol Surrena Telephone: 330-534-0800 E-mail: email@example.com
|SOURCE NanoLogix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved